FDA Approves Pembrolizumab for Microsatellite Instability-High and Mismatch Repair Deficient Cancers
May 23, 2017 - The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed ...Leggi tutto